On the five-year anniversary of the Global Diabetes Compact, WHO has issued a call to manufacturers to submit requests for “prequalification” of generic versions of the GLP-1 drug semaglutide for diabetes management – the drug that initially became famous for weight-loss – as well as fast-acting insulin analogues that have gained popularity over human insulin … Continue reading WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug